看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
0 O. ?5 e& n. s+ R6 c
7 y" t" s, C; Q
$ ?# F% M! W+ Y/ J& b) K2 O$ u, [$ SCurrently available feasibility data for possible combination strategies. - [" ]' x% p9 R; ^
————————————————————————————————
3 W$ E6 O0 [2 Z) f! a; b1 N2 NCombination Feasibility according to preliminary data
& S/ g0 m& }# [8 ^8 N: b! i——————————————————————————————————7 g, I5 U. k3 T$ ]8 I c1 q
Bevacizumab + sorafenib Yes, reduced dose
1 ~7 ?( V! K5 e" h, L: bBevacizumab + sunitinib† No 1 I6 `+ |$ ?9 Z1 F: a( r9 \
Bevacizumab + temsirolimus Yes
: D6 g7 q/ B$ t; \" x zBevacizumab + everolimus Yes 1 ]/ w- [+ c" F7 A. ^
Sorafenib + sunitinib ? # }0 ]" [, n" y% j* |
Sorafenib + temsirolimus Yes, reduced dose
% _2 Z4 [% L1 u: i( ^/ d9 ^. RSorafenib + everolimus Yes, reduced dose
' ~5 V+ Q! |! }" X4 VSunitinib + temsirolimus† No & p) v/ e! z( c; D7 r: K
Sunitinib + everolimus ? 3 O4 D& V; W2 M0 W3 U2 r9 t6 O
Temsirolimus + everolimus ? / r' n9 Z+ q6 J, I2 s; O
————————————————————# w, w1 R9 ~' B& |. |/ d
†Led to US FDA warning.
0 y# Q6 O' _4 r k& W3 y?: As yet unattempted combination.* t, J2 f# G% I) K& Z$ H; q7 z
|